Bausch Health Companies Inc (BHC)

$6.35

-0.02

(-0.31%)

Market is closed - opens 7 PM, 24 May 2024

Insights on Bausch Health Companies Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.40B → 2.14B (in $), with an average decrease of 11.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 395.0M → -63.71M (in $), with an average decrease of 116.1% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 51.7% return, outperforming this stock by 75.0%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 46.7% return, outperforming this stock by 126.4%

Performance

  • $6.26
    $6.42
    $6.35
    downward going graph

    1.42%

    Downside

    Day's Volatility :2.49%

    Upside

    1.09%

    downward going graph
  • $6.26
    $11.46
    $6.35
    downward going graph

    1.42%

    Downside

    52 Weeks Volatility :45.38%

    Upside

    44.59%

    downward going graph

Returns

PeriodBausch Health Companies IncSector (Health Care)Index (Russel 2000)
3 Months
-29.37%
-2.0%
0.0%
6 Months
-8.37%
10.5%
0.0%
1 Year
-23.31%
12.2%
0.0%
3 Years
-79.73%
16.4%
-20.6%

Highlights

Market Capitalization
2.3B
Book Value
- $3.04
Earnings Per Share (EPS)
-1.24
PEG Ratio
0.63
Wall Street Target Price
9.83
Profit Margin
-5.08%
Operating Margin TTM
13.89%
Return On Assets TTM
4.04%
Return On Equity TTM
-686.52%
Revenue TTM
9.0B
Revenue Per Share TTM
24.51
Quarterly Revenue Growth YOY
10.8%
Gross Profit TTM
5.8B
EBITDA
3.0B
Diluted Eps TTM
-1.24
Quarterly Earnings Growth YOY
1.12
EPS Estimate Current Year
3.63
EPS Estimate Next Year
4.21
EPS Estimate Current Quarter
0.72
EPS Estimate Next Quarter
0.87

Analyst Recommendation

Buy
    50%Buy
    50%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Bausch Health Companies Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
4
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 54.8%

Current $6.35
Target $9.83

Company Financials

FY18Y/Y Change
Revenue
8.4B
↓ 3.94%
Net Income
-4.1B
↓ 272.55%
Net Profit Margin
-49.5%
↓ 77.06%
FY19Y/Y Change
Revenue
8.6B
↑ 2.64%
Net Income
-1.8B
↓ 57.02%
Net Profit Margin
-20.73%
↑ 28.77%
FY20Y/Y Change
Revenue
8.0B
↓ 6.67%
Net Income
-559.0M
↓ 68.65%
Net Profit Margin
-6.96%
↑ 13.77%
FY21Y/Y Change
Revenue
8.4B
↑ 5.07%
Net Income
-937.0M
↑ 67.62%
Net Profit Margin
-11.11%
↓ 4.15%
FY22Y/Y Change
Revenue
8.1B
↓ 3.68%
Net Income
-212.0M
↓ 77.37%
Net Profit Margin
-2.61%
↑ 8.5%
FY23Y/Y Change
Revenue
8.8B
↑ 7.79%
Net Income
-592.0M
↑ 179.25%
Net Profit Margin
-6.76%
↓ 4.15%
Q4 FY22Q/Q Change
Revenue
2.2B
↑ 7.18%
Net Income
-410.0M
↓ 202.76%
Net Profit Margin
-18.7%
↓ 38.2%
Q1 FY23Q/Q Change
Revenue
1.9B
↓ 11.35%
Net Income
-209.0M
↓ 49.02%
Net Profit Margin
-10.75%
↑ 7.95%
Q2 FY23Q/Q Change
Revenue
2.2B
↑ 11.47%
Net Income
26.0M
↓ 112.44%
Net Profit Margin
1.2%
↑ 11.95%
Q3 FY23Q/Q Change
Revenue
2.2B
↑ 3.28%
Net Income
-378.0M
↓ 1553.85%
Net Profit Margin
-16.89%
↓ 18.09%
Q4 FY23Q/Q Change
Revenue
2.4B
↑ 7.6%
Net Income
395.0M
↓ 204.5%
Net Profit Margin
16.4%
↑ 33.29%
Q1 FY24Q/Q Change
Revenue
2.1B
↓ 10.99%
Net Income
-63.7M
↓ 116.13%
Net Profit Margin
-2.97%
↓ 19.37%
FY18Y/Y Change
Total Assets
27.4B
↓ 26.8%
Total Liabilities
24.6B
↓ 21.93%
FY19Y/Y Change
Total Assets
33.9B
↑ 23.38%
Total Liabilities
32.7B
↑ 32.86%
FY20Y/Y Change
Total Assets
31.2B
↓ 7.87%
Total Liabilities
30.6B
↓ 6.52%
FY21Y/Y Change
Total Assets
29.2B
↓ 6.4%
Total Liabilities
29.2B
↓ 4.44%
FY22Y/Y Change
Total Assets
25.7B
↓ 12.04%
Total Liabilities
25.4B
↓ 13.03%
FY23Y/Y Change
Total Assets
27.4B
↑ 6.48%
Total Liabilities
27.4B
↑ 7.89%
Q4 FY22Q/Q Change
Total Assets
25.7B
↓ 2.33%
Total Liabilities
25.4B
↓ 1.7%
Q1 FY23Q/Q Change
Total Assets
25.4B
↓ 0.94%
Total Liabilities
25.3B
↓ 0.5%
Q2 FY23Q/Q Change
Total Assets
33.8B
↑ 32.82%
Total Liabilities
33.4B
↑ 32.16%
Q3 FY23Q/Q Change
Total Assets
27.1B
↓ 19.92%
Total Liabilities
27.3B
↓ 18.36%
Q4 FY23Q/Q Change
Total Assets
27.4B
↑ 1.06%
Total Liabilities
27.4B
↑ 0.49%
Q1 FY24Q/Q Change
Total Assets
26.9B
↓ 1.7%
Total Liabilities
27.1B
↓ 1.36%
FY18Y/Y Change
Operating Cash Flow
1.5B
↓ 34.45%
Investing Cash Flow
-196.0M
↓ 106.79%
Financing Cash Flow
-1.4B
↓ 72.74%
FY19Y/Y Change
Operating Cash Flow
1.5B
↑ 0.0%
Investing Cash Flow
-419.0M
↑ 113.78%
Financing Cash Flow
1.4B
↓ 206.65%
FY20Y/Y Change
Operating Cash Flow
1.1B
↓ 25.98%
Investing Cash Flow
-261.0M
↓ 37.71%
Financing Cash Flow
-2.3B
↓ 258.97%
FY21Y/Y Change
Operating Cash Flow
1.4B
↑ 28.35%
Investing Cash Flow
409.0M
↓ 256.7%
Financing Cash Flow
-1.5B
↓ 34.05%
FY22Y/Y Change
Operating Cash Flow
-728.0M
↓ 151.05%
Investing Cash Flow
-303.0M
↓ 174.08%
Financing Cash Flow
-474.0M
↓ 68.67%
Q4 FY22Q/Q Change
Operating Cash Flow
475.0M
↓ 137.61%
Investing Cash Flow
-303.0M
↑ 81.44%
Financing Cash Flow
-276.0M
↑ 666.67%
Q1 FY23Q/Q Change
Operating Cash Flow
154.0M
↓ 67.58%
Investing Cash Flow
-78.0M
↓ 74.26%
Financing Cash Flow
-142.0M
↓ 48.55%
Q2 FY23Q/Q Change
Operating Cash Flow
268.8M
↑ 74.53%
Investing Cash Flow
-30.0M
↓ 61.54%
Financing Cash Flow
-155.1M
↑ 9.25%
Q3 FY23Q/Q Change
Operating Cash Flow
282.0M
↑ 4.92%
Investing Cash Flow
-2.0B
↑ 6556.67%
Financing Cash Flow
1.8B
↓ 1270.59%

Technicals Summary

Sell

Neutral

Buy

Bausch Health Companies Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bausch Health Companies Inc
Bausch Health Companies Inc
-25.82%
-8.37%
-23.31%
-79.73%
-73.0%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
1.11%
25.27%
51.72%
46.65%
75.88%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
1.32%
-1.28%
1.68%
14.17%
14.17%
Zoetis Inc.
Zoetis Inc.
13.27%
-5.17%
1.04%
-3.12%
66.89%
Viatris Inc.
Viatris Inc.
-8.83%
11.66%
16.61%
-31.45%
-35.56%
Catalent, Inc.
Catalent, Inc.
-2.32%
36.66%
45.97%
-46.71%
18.21%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bausch Health Companies Inc
Bausch Health Companies Inc
71.75
NA
0.63
3.63
-6.87
0.04
NA
-3.04
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
38.2
38.2
0.44
4.06
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.33
28.33
1.69
0.46
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
33.09
33.09
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.25
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bausch Health Companies Inc
Bausch Health Companies Inc
Buy
$2.3B
-73.0%
71.75
-5.08%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
75.88%
38.2
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.8B
14.17%
28.33
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$78.5B
66.89%
33.09
27.38%
Viatris Inc.
Viatris Inc.
Hold
$12.9B
-35.56%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$9.9B
18.21%
211.02
-28.44%

Institutional Holdings

  • ICAHN CARL C

    9.47%
  • Goldentree Asset Management LP

    7.54%
  • Paulson & Company Inc

    7.21%
  • Franklin Resources Inc

    4.31%
  • Nomura Holdings Inc

    4.19%
  • HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND

    3.54%

Company Information

bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###

Organization
Bausch Health Companies Inc
Employees
20270
CEO
Mr. Thomas J. Appio
Industry
Health Technology

FAQs